Skip to main content
. 2018 Jun 20;9(8):1012–1017. doi: 10.1111/1759-7714.12779

Table 1.

Clinical characteristics of patients with EGFR‐mutant NSCLC according to first progression site

N = 21 No %
Gender
Male 7 46.7
Female 8 53.3
Age (years)
Median 54.2
Range 29–81
Histology
Adenocarcinoma 14 93.3
Squamous cell carcinoma 1 6.7
ECOG PS
0 2 13.3
1 10 66.7
2 3 20.0
Smoking history
Never 11 73.3
Former 4 16.7
EGFR mutation type
19 del 9 60.0
21 L858R 5 33.3
18 G719X 1 6.7
Best response to TKI
CR 2 13.3
PR 8 53.4
SD 5 33.3
Line of EGFR‐TKI
First‐line 9 60
Second/third‐line 6 40
Site of RECIST PD
Lung 10 66.7
Liver 4 16.6
Adrenal 1 6.7

CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non‐small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.